Techinvention

What Techinvention does

TechInvention Lifecare Pvt. Ltd. is a Mumbai-based vaccine biotechnology company founded in 2016 that develops and manufactures affordable vaccines and biopharmaceuticals for low- and middle-income countries. The company operates an integrated platform spanning recombinant subunit and glycoconjugate vaccine development using a proprietary Pichia pastoris expression system, biotherapeutics including novel phage-encoded lysins targeting antimicrobial-resistant infections, and a diagnostics portfolio. Its current commercial offering centers on Euvichol-Plus, a WHO-prequalified oral cholera vaccine launched in India in 2023 in partnership with Eubiologics Co., Ltd. The R&D pipeline spans pneumococcal, meningococcal (ACYWX+B and serogroup B), malaria, tuberculosis (Hsp16.3C4), hepatitis B, shigella, salmonella, and varicella vaccines, with technology transfer agreements from ICMR, IIT Bhubaneswar, and Institute of Life Sciences.

The company serves three primary customer segments: (1) governments and national immunization programs in LMICs seeking affordable vaccine supply (ICMR, Ethiopia Ministry of Health); (2) biopharmaceutical companies requiring contract development and manufacturing (CDMO) services for GMP-scale vaccine production and technology licensing; and (3) international health organizations (WHO, UNOPS) for training, biosafety, and global health initiatives. Distribution channels combine direct government/B2B sales, licensing royalties, and technology transfer agreements, with no public pricing disclosure as contracts are individually negotiated.

TechInvention generates revenue through managed CDMO services, licensing royalties on proprietary vaccine technologies, and product sales (primarily Euvichol-Plus). Manufacturing infrastructure includes the HORIZON GMP-like preclinical facility in Navi Mumbai and the GCMC EU-GMP-compliant commercial facility, also in Navi Mumbai, which is nearing launch. The company has secured technology transfer agreements with ICMR covering 27 public health technologies, strategic advisory roles for Ethiopia's vaccine manufacturing initiative, supervision of Botswana Vaccine Institute's cGMP facility build, and an RNA manufacturing partnership with Quantoom Biosciences. Leadership is provided by CEO Syed S. Ahmed; the company operates as a private limited entity with disclosed investment from Ashish Kacholia and a Dun & Bradstreet Lowest Risk SME rating (score of 81).

Name

Techinvention

Legal name

Techinvention Lifecare Pvt. Ltd.

Website

https://techinvention.biz

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

TechInvention Lifecare is a Mumbai-based vaccine biotech that develops affordable recombinant and conjugate vaccines, biotherapeutics, and diagnostics for low- and middle-income countries, serving governments, biopharma firms, and global health organizations via CDMO services, licensing, and its EU-GMP manufacturing facility.

Ownership category

akta.pro rank

Product category

Vaccines & Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

akta.pro secondary industries

Process Development & Tech Transfer Services (CDMO) (HLAGABAL), Travel & Tropical Disease Vaccines (HLAIAEAE), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM)

Keywords

• Vaccine development
• Biopharmaceutical manufacturing
• Contract development manufacturing
• Recombinant vaccine platform
• Vaccine technology licensing

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Vaccine Manufacturing & CDMO Services: Contract development and manufacturing services for biotech companies and research institutions requiring GMP-scale vaccine production. Revenue from technology transfer, scale-up services, and commercial manufacturing agreements.
2. Licensing Royalties: Technology licensing agreements with pharmaceutical companies for commercialization of proprietary vaccine technologies and formulations.
3. Product Sales: Direct sales of vaccine products including Euvichol-Plus oral cholera vaccine and in-house developed vaccine candidates upon regulatory approval.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

TechInvention is a Mumbai-based vaccine biotechnology company that develops, manufactures, and commercializes affordable vaccines and biopharmaceuticals for low- and middle-income countries. It operates an integrated ecosystem spanning R&D, technology transfer, GMP-compliant manufacturing (GCMC), and contract development and manufacturing (CDMO) services, with proprietary platforms including the Pichia pastoris recombinant expression system and glycoconjugate vaccine technology. Key focus areas include vaccines for cholera, tuberculosis, malaria, meningitis, pneumonia, and hepatitis, alongside biotherapeutics (phage-encoded lysins) and diagnostics.

Product overview

TechInvention Lifecare Limited is a Mumbai-based vaccine biotechnology company that operates a multi-faceted portfolio comprising (1) an R&D vaccine pipeline with candidates including Pneumococcal Conjugate Vaccine 16-valent, Hexavalent Meningococcal Vaccine ACYWX+B, Meningococcal B Vaccine, Malaria Vaccine, Tuberculosis Vaccine (Hsp16.3C4), Hepatitis B Vaccine, Shigella Vaccine, and Salmonella Typhi & Paratyphi Vaccine; (2) in-licensed/regulatory-stage products including OCV, Varicella Vaccine, Tdap Vaccine, QIV, and Hepatitis A Vaccine; (3) the commercial product Euvichol-Plus (oral cholera vaccine); (4) diagnostic products and biotherapeutics (phage-encoded lysins); (5) manufacturing infrastructure including HORIZON (GMP-like preclinical facility) and GCMC (EU-GMP-compliant commercial facility in Navi Mumbai); and (6) services including Strategic & Technical Advisory, Global Access/Licensing, and CDMO services. The company focuses on enabling vaccine and biotherapeutic development for low- and middle-income countries through an integrated ecosystem from concept to commercialization.

Differentiator

Problem solved

Functional benefit

Brands

• GCMC: Global Collaborative Centre for Medical Countermeasures - An EU-GMP-compliant facility purpose-built to enable seamless scale-up and accelerate the translation of vaccine candidates from pre-clinical stage through clinical development to full-scale commercialization.
• HORIZON

Products and services

• Euvichol-Plus Oral Cholera Vaccine World's first oral cholera vaccine in an LDPE unidose pack, launched in collaboration with Eubiologics Co., Ltd.; WHO-prequalified; commercialized in India for government immunization programs and global health initiatives.
• Contract Development and Manufacturing (CDMO) Services Contract development and manufacturing services for scale-ups and commercial production of vaccines and biologics, serving domestic and international biotech and pharmaceutical clients requiring GMP vaccine production.
• Strategic & Technical Advisory Consulting services for capacity building and strategic guidance in vaccine and biopharmaceutical development, including advisory roles for national vaccine manufacturing initiatives.
• Global Access / In & Out Licensing Licensing services facilitating technology transfer and global access to vaccines and biopharmaceuticals, including licensing of proprietary technologies to pharmaceutical partners for commercialization.
• Diagnostics Portfolio Comprehensive range of diagnostics for human and veterinary segments developed in collaboration with RIVDR for global supply, including infectious disease diagnostics.

Quantifiable outcome

• 41 technology transfer deals signed with ICMR formalizing 27 technologies
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core, major and minor.

• ICMR (Indian Council of Medical Research)coreTechnology or Integration · 25 May 2026TechInvention secured technology transfer agreements with ICMR for GMP scale-up of a recombinant malaria vaccine and technology transfer for next-generation recombinant TB vaccine. The company was selected as a partner for public health technology transfers covering 27 technologies including glycoconjugate vaccines, diagnostic technologies, and biomaterials.
• IIT BhubaneswarcoreStrategic or Co-development Partner · 24 November 2025Quadripartite license agreement with IIT Bhubaneswar and Institute of Life Sciences for India's first indigenous next-generation subunit TB vaccine 'Hsp16.3C4'. TechInvention received technology transfer for scale-up and commercialization of the vaccine that completed preclinical trials.
• Institute of Life Sciences (ILS)coreStrategic or Co-development Partner · 24 November 2025Collaboration with IIT Bhubaneswar and ILS Bhubaneswar for development and commercialization of next-generation recombinant TB vaccine 'Hsp16.3C4', targeting latency-associated antigen of Mycobacterium tuberculosis.
• Quantoom BiosciencescoreStrategic or Co-development Partner · 1 January 2025Landmark partnership with Quantoom Biosciences to enhance India's GMP RNA manufacturing capabilities. The partnership focuses on delivering innovative, accessible, and scalable RNA-based vaccines and therapies.
• Ethiopia Ministry of HealthmajorImplementation/ SI/ Consulting Partner · 1 January 2025TechInvention appointed as advisor for Ethiopia's landmark vaccine manufacturing project. Strategic advisory role to strengthen Africa's journey toward vaccine self-reliance and health system resilience.
• UNOPSminorStrategic or Co-development Partner · 1 January 2025Second UNOPS project secured to deliver hands-on training on end-to-end vaccine analytics. Training involves 2 weeks of virtual sessions followed by 8 weeks of immersive hands-on training at HORIZON facility.
• National Research Development Corporation (NRDC)coreChannel Partner/ Reseller/ Distributor · 1 January 2025Quadripartite partnership with NRDC for scaling up and commercializing the cutting-edge recombinant tuberculosis vaccine developed by IIT Bhubaneswar and Institute of Life Sciences.
• Botswana Vaccine Institute (BVI)majorStrategic or Co-development Partner · 1 January 2024TechInvention appointed to supervise the creation of a state-of-the-art cGMP-compliant veterinary vaccine manufacturing unit in Gaborone, Botswana. Project set to be operational by 2026 to enhance BVI's vaccine capacity and quality.
• Eubiologics Co., Ltd.majorTechnology or Integration · 1 January 2023Partnership for launch of Euvichol-Plus, the world's first oral cholera vaccine in LDPE unidose pack. TechInvention enabled enhanced accessibility and safety of WHO-prequalified cholera vaccine supporting WHO's goal to end cholera by 2030.
• Reagent IVD Resources Pvt. Ltd. (RIVDR)minorStrategic or Co-development Partner · 1 January 2023Strategic collaboration with RIVDR, a Jaipur-based diagnostics-focused start-up, for development and manufacturing of comprehensive diagnostics range covering human and veterinary segments for global supplies.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Bharat Biotech: India-headquartered vaccine manufacturer with broad portfolio including oral cholera vaccines, typhoid conjugates, and a comprehensive R&D/CDMO footprint. Closest peer to TechInvention given shared Indian base, WHO-prequalified product catalog, LMIC focus, and combined R&D + manufacturing model.
• Biological E. Limited: Hyderabad-based vaccine and biologics CDMO with WHO-prequalified products targeting LMICs, including pentavalent and Japanese encephalitis vaccines. Directly comparable as India-based integrated vaccine developer + contract manufacturer serving government immunization programs.
• Panacea Biotec: Indian vaccine and biopharmaceutical company with WHO-prequalified pediatric combination vaccines and a CDMO business. Comparable in scale, India base, government-tender focus, and combined proprietary vaccines + contract manufacturing revenue model.
• Indian Immunologicals Limited: India-based manufacturer of both human and veterinary vaccines (including through BVI-equivalent partnerships) with strong government relationships. Highly relevant peer given TechInvention's BVI veterinary advisory role and shared Indian-government anchored business model.
• Eubiologics Co., Ltd. South Korean oral cholera vaccine specialist and TechInvention's commercial partner for Euvichol-Plus in India. Directly comparable as a focused cholera/LMIC vaccine developer relying on regional commercialization partners for scale.

Broad incumbents

• Serum Institute of India: The world's largest vaccine manufacturer by doses, based in Pune with extensive WHO-prequalified vaccines for LMICs. Functions as a broad incumbent in the same vaccine categories TechInvention targets (cholera, meningitis, pneumococcal, TB), but at vastly greater scale and with vertically integrated R&D.
• Sanofi Pasteur: Global vaccine major with deep portfolio across pediatric, travel, and emerging-disease vaccines. Represents the broader incumbent competitive set in meningitis, cholera, and TB categories where TechInvention competes or aspires to license-in technologies.
• GSK Vaccines: One of the world's largest vaccine businesses with broad portfolio including meningitis, hepatitis, and TB candidates. Relevant as a benchmark for global commercial scale and as a potential licensing partner for TechInvention's pipeline candidates.

Emerging players

• Hilleman Laboratories: Singapore-based nonprofit vaccine R&D organization focused on affordable vaccines for LMICs, with technology transfer and development partnerships. Comparable as a similarly-sized vaccines-for-Global-South developer whose capabilities and partnership networks overlap with TechInvention's pipeline focus.

Regional players

• Vabiotech (VABNACO): Vietnamese state-owned vaccine manufacturer producing a range of WHO-prequalified vaccines and now building new cGMP capacity. Comparable as an Asia-based emerging-market vaccine manufacturer scaling capacity for government immunization programs, though operating in a different national context.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?app=desktop&v=gUu74r44UbI
• LinkedInlinkedin.com/company/techinvention
• Xx.com/TechinventionL

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Techinvention